PLK1 and neoplasm: Hence, under our five-gene risk score classification, the high-risk MPM patients may benefit from PLK1 specific small molecule inhibitors, which are currently considered to be attractive therapeutic strategies against specific tumor types such as leukemia and non-small cell lung cancer (Medema et al., 2011; Lee et al., 2015).